Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

OBIO Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Orchestra BioMed Holdings, Inc.NASDAQ: OBIO

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 54.6% from a year ago

Cash & equivalents stood at $28.37M at the end of Q1 FY2026, up 54.6% from a year earlier and down 18.2% from the prior quarter. Over 3 fiscal years it compounded at +20.6% a year.

Context

  • Cash & equivalents amounted to 28.2% of total assets at the end of Q1 FY2026, down 2.9 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +54.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$28.37M-18.2% QoQ
Last fiscal yearDec 2025
$34.69M+55.8% YoY
Year agoMar 2025
$18.35M+54.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+54.6%——
1 year+55.8%——
3-year CAGR+20.6%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
34.69M USD
Year-over-year change
+55.8%
4-year CAGR
+36.7%

Cash & Equivalents vs competitors

How OBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +54.6% is the 3rd highest of 11, against a peer median of -42.6%.
  • Cash & equivalents amounts to 28.2% of total assets for OBIO, versus a peer median of 21.6%.
OBIO Competitors
Cash & Equivalents for OBIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IVVDInvivyd, Inc.Mar 2026$184.15M USD+283.0%+35.0%76.2%
IVAInventiva S.A.Dec 2025€99.27M EUR+2.8%+4.6%39.9%
TNYATenaya Therapeutics, Inc.Mar 2026$80.89M USD+50.4%+1.8%59.9%
EPRXEupraxia Pharmaceuticals Inc.Mar 2026$58.69M USD+113.8%+48.2%40.2%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$34.93M USD-42.0%-9.8%11.1%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026$28.37M USD+54.6%+20.6%28.2%
AVTXAvalo Therapeutics, Inc.Mar 2026$24.99M USD-80.0%+6.4%25.0%
PRLDPrelude Therapeutics IncorporatedMar 2026$21.76M USD-46.0%+4.8%18.2%
TARAProtara Therapeutics, Inc.Mar 2026$14.74M USD-83.9%+27.2%7.7%
CRBUCaribou Biosciences, Inc.Mar 2026$12.06M USD-59.0%-40.4%8.1%
PYXSPyxis Oncology, Inc.Mar 2026$7.24M USD-43.3%-55.9%11.3%
Peer median (excluding OBIO) —-42.6%+4.7%21.6%

Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents9.94M19.78M30.56M22.26M34.69M
Short-term Investments958K64M57.04M44.55M71.82M
Net Receivables121K96K99K92K95K
Inventory68K276K146K173K310K
Other Current Assets0533K1.27M2.09M994K
Total Current Assets11.32M84.69M89.11M69.17M107.91M
Property, Plant & Equipment (Net)1.12M3.68M2.83M3.49M3.21M
Goodwill00000
Intangible Assets00000
Long-term Investments398K2.5M2.5M2.5M2.5M
Tax Assets00000
Other Non-current Assets690K4.71M769K1.02M1.24M
Total Non-current Assets2.21M10.88M6.1M7M6.95M
Total Assets13.53M95.57M95.21M76.17M114.86M
Account Payables2.03M3.97M2.9M5.13M6.1M
Short-term Debt2M000751K
Tax Payables1K0000
Deferred Revenue5.54M6.44M2.51M4.44M0
Other Current Liabilities2M4.57M2.66M2.61M9.89M
Total Current Liabilities12.24M18.57M11.21M16.21M16.74M
Long-term Debt3.67M9.49M014.29M936K
Deferred Tax Liabilities00(14.92M)00
Deferred Revenue (Non-current)16.86M13.1M14.92M10.99M0
Other Non-current Liabilities51.99M196K14.92M40K33.81M
Total Non-current Liabilities72.52M24.47M15.96M27.01M34.74M
Total Liabilities84.76M43.04M27.17M43.22M51.48M
Common Stock160M2K4K4K6K
Retained Earnings(166.13M)(199.73M)(248.85M)(309.88M)(362.58M)
Accumulated OCI(211.45M)(8K)(10K)52K60K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(71.23M)52.53M68.04M32.96M63.38M
Total Debt5.67M11.87M1.69M16.53M1.69M
Net Debt(4.27M)(7.91M)(28.87M)(5.73M)(33M)

Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Intrinsic Alpha fair value

Locked

Current Price

$7.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.